Calidi Biotherapeutics, Inc. expanded its Board of Directors from five to six members by appointing Dr. Corazon (Corsee) Sanders as a Class III director with a term expiring at the 2029 annual meeting. Dr. Sanders will also serve on the Audit Committee, replacing Scott Leftwich on that committee. Calidi Biotherapeutics, Inc. is a biotechnology company focused on developing therapies for cancer and infectious diseases.
